[Immunointervention in newly diagnosed type 1 diabetes].
Kaupper
T
T
Institut für Diabetesforschung, München. prevent.diabetes@lrz.uni-muenchen.de
Walter
M
M
Ziegler
A-G
AG
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000069059:Atorvastatin; D001327:Autoimmune Diseases / Q000276:immunology*; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology* / Q000517:prevention & control / Q000628:therapy*; D006538:Heptanoic Acids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D050417:Insulin-Secreting Cells / Q000276:immunology / Q000473:pathology; D011236:Prediabetic State / Q000276:immunology* / Q000628:therapy; D011758:Pyrroles / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D006538:Heptanoic Acids; D007166:Immunosuppressive Agents; D011758:Pyrroles; D000069059:Atorvastatin